

Remarks/Arguments

Status of the Application

In the present response, Claims 15-18, 23-26 and 29-32 have been canceled and claim 19 amended to place in independent form. As a result, claims 13, 14, 20-22, 27 and 28 are allowed and claim 19 objected to. Applicants thank the Office for identifying the allowable subject matter.

The above amendments have been made without prejudice to Applicants' right to prosecute any cancelled subject matter in a timely filed continuation application.

Objection

Claim 19 was objected to as allegedly "being of improper dependent form for failing to further limit the subject matter of a previous claim." Applicants respectfully assert that this objection has been rendered moot via the amendment placing claim 19 in independent form. Accordingly, Applicants respectfully request the Office to withdraw this objection.

Summary

In view of the foregoing amendments and remarks, Applicants respectfully submit that in addition to claims 13, 14, 20-22, 27 and 28, claim 19 is also now allowable. Accordingly, Applicants respectfully solicit a Notice of Allowance. In order to expedite disposition of this case, the Office is invited to contact Applicants' representative at the telephone number below to resolve any remaining issues. Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 100647-1P US.

Respectfully submitted,

/Jacqueline M. Cohen/

Global Intellectual Property,
Patents, AstraZeneca
1800 Concord Pike
Wilmington
DE-19850-5437

Name: Jacqueline M. Cohen
Dated: 10/30/2007
Reg. No.: 51,574
Phone No.: 302-885-4269